Epidermal growth factor receptor (EGFR) pathway genes and interstitial lung disease: An association study

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Li, Chong ^a,b   Wei, Rongrong ^a   Jones Hall, Yava L ^c   Vittal, Ragini ^d   Zhang, Min ^e   Liu, Wanqing ^a,f  

^a PURDUE UNIVERSITY   (United States)

^b THE THIRD AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^c PURDUE UNIVERSITY   (United States)

^d INDIANA UNIVERSITY   (United States)

^e PURDUE UNIVERSITY   (United States)

^f PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR;

AGED; ALLELE; CASE CONTROL STUDY; FEMALE; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; HUMAN; INTERSTITIAL LUNG DISEASE; MALE; MIDDLE AGED; RISK; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; ALLELES; CASE-CONTROL STUDIES; EPIDERMAL GROWTH FACTOR; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RISK; RISK FACTORS;

EID: 84900464331     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep04893     Document Type: Article

References (50)

1. Grutters, J. C. & du Bois, R. M. Genetics of fibrosing lung diseases. Eur Respir J 25, 915-27 (2005). (Pubitemid 40667693)
2. Allam, J. S. & Limper, A. H. Idiopathic pulmonary fibrosis: is it a familial disease? Curr Opin Pulm Med 12, 312-7 (2006). (Pubitemid 44315774)
3. Clement, A., Henrion-Caude, A. & Fauroux, B. The pathogenesis of interstitial lung diseases in children. Paediatr Respir Rev 5, 94-7 (2004). (Pubitemid 38701806)
4. Raghu, G., Nyberg, F. & Morgan, G. The epidemiology of interstitial lung disease and its association with lung cancer. Br J Cancer 91 Suppl 2, S3-10 (2004).
5. Noth, I. & Martinez, F. J. Recent advances in idiopathic pulmonary fibrosis. Chest 132, 637-50 (2007). (Pubitemid 47282399)
6. Behr, J. Evidence-based treatment strategies in idiopathic pulmonary fibrosis. Eur Respir Rev 22, 163-8 (2013).
7. Steele, M. P. & Brown, K. K. Genetic predisposition to respiratory diseases: infiltrative lung diseases. Respiration 74, 601-8 (2007). (Pubitemid 350164503)
8. Santangelo, S. et al. Genetic background of idiopathic pulmonary fibrosis. Expert Rev Mol Diagn 13, 389-406 (2013).
9. Tsakiri, K. D. et al. Adult-onset pulmonary fibrosis caused by mutations in telomerase. Proc Natl Acad Sci U S A 104, 7552-7 (2007). (Pubitemid 47185944)
10. Nogee, L. M. et al. A mutation in the surfactant protein C gene associated with familial interstitial lung disease. N Engl J Med 344, 573-9 (2001). (Pubitemid 32167871)
11. Wang, Y. et al. Genetic defects in surfactant protein A2 are associated with pulmonary fibrosis and lung cancer. Am J Hum Genet 84, 52-9 (2009).
12. Mushiroda, T. et al. Agenome-wide association study identifies an association of a common variant in TERT with susceptibility to idiopathic pulmonary fibrosis. J Med Genet 45, 654-6 (2008).
13. Fingerlin, T. E. et al. Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. Nat Genet 45, 613-20 (2013).
14. Seibold, M. A. et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med 364, 1503-12 (2011).
15. Noth, I. et al. Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study. The Lancet Respiratory Medicine 1, 9 (2013).
16. Hunninghake, G. M. et al. MUC5B promoter polymorphism and interstitial lung abnormalities. N Engl J Med 368, 2192-200 (2013).
17. Kato, T. & Nishio, K. Clinical aspects of epidermal growth factor receptor inhibitors: benefit and risk. Respirology 11, 693-8 (2006). (Pubitemid 44581432)
18. Sandler, A. B. Nondermatologic adverse events associated with anti-EGFR therapy. Oncology (Williston Park) 20, 35-40 (2006).
19. Lenz, H. J. Anti-EGFR mechanism of action: antitumor effect and underlying cause of adverse events. Oncology (Williston Park) 20, 5-13 (2006).
20. Tsuboi, M. & Le Chevalier, T. Interstitial lung disease in patients with non-smallcell lung cancer treated with epidermal growth factor receptor inhibitors. Med Oncol 23, 161-70 (2006). (Pubitemid 43785965)
21. Higenbottam, T., Kuwano, K., Nemery, B. & Fujita, Y. Understanding the mechanisms of drug-associated interstitial lung disease. Br J Cancer 91 Suppl 2, S31-7 (2004). (Pubitemid 39331429)
22. Fukui, T. & Mitsudomi, T. Mutations in the epidermal growth factor receptor gene and effects of EGFR-tyrosine kinase inhibitors on lung cancers. Gen Thorac Cardiovasc Surg 56, 97-103 (2008). (Pubitemid 351419126)
23. Yoneda, K. Y., Shelton, D. K., Beckett, L. A. & Gandara, D. R. Independent review of interstitial lung disease associated with death in TRIBUTE (paclitaxel and carboplatin with or without concurrent erlotinib) in advanced non-small cell lung cancer. J Thorac Oncol 2, 537-43 (2007). (Pubitemid 47171809)
24. Liu, W. et al. A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter. Cancer Res 65, 46-53 (2005). (Pubitemid 40070794)
25. Liu, W. et al. Relationship of EGFR mutations, expression, amplification, and polymorphisms to epidermal growth factor receptor inhibitors in the NCI60 cell lines. Clin Cancer Res 13, 6788-95 (2007). (Pubitemid 350206817)
26. Moriai, T., Kobrin, M. S. & Korc, M. Cloning of a variant epidermal growth factor receptor. Biochem Biophys Res Commun 191, 1034-9 (1993). (Pubitemid 23231594)
27. Moriai, T., Kobrin, M. S., Hope, C., Speck, L. & Korc, M. A variant epidermal growth factor receptor exhibits altered type alpha transforming growth factor binding and transmembrane signaling. Proc Natl Acad Sci U S A 91, 10217-21 (1994). (Pubitemid 24311980)
28. Liu, W. & Ratain, M. J. An intronic polymorphism determines TGF-alpha expression and is associated with cellular resistance to erlotinib. Cancer Res 70, Suppl 1: Abstract 2608, (2010).
29. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 165, 277-304 (2002).
30. Sasaki, H. et al. EGFR R497K polymorphism is a favorable prognostic factor for advanced lung cancer. J Cancer Res Clin Oncol 135, 313-8 (2009).
31. Flom, P. L. & Cassell, D. L. Stopping stepwise: Why stepwise and similar selection methods are bad, and what you should use. in Conference Proceedings of NESUG 2007 edn (2007).
32. Purcell, S. et al. PLINK: a tool set for whole-genome association and populationbased linkage analyses. American Journal of Human Genetics 81, 559-75 (2007). (Pubitemid 47330214)
33. Kudoh, S. et al. Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. Am J Respir Crit Care Med 177, 1348-57 (2008). (Pubitemid 351860912)
34. Hetzel, M., Bachem, M., Anders, D., Trischler, G. & Faehling, M. Different effects of growth factors on proliferation and matrix production of normal and fibrotic human lung fibroblasts. Lung 183, 225-37 (2005). (Pubitemid 41428095)
35. Baughman, R. P., Lower, E. E., Miller, M. A., Bejarano, P. A. & Heffelfinger, S. C. Overexpression of transforming growth factor-alpha and epidermal growth factor-receptor in idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 16, 57-61 (1999). (Pubitemid 29164271)
36. Geiser, T. Mechanisms of alveolar epithelial repair in acute lung injury-a translational approach. Swiss Med Wkly 133, 586-90 (2003). (Pubitemid 38017061)
37. Nielsen, H. C., Martin, A., Volpe, M. V., Hatzis, D. & Vosatka, R. J. Growth factor control of growth and epithelial differentiation in embryonic lungs. Biochem Mol Med 60, 38-48 (1997). (Pubitemid 27198148)
38. Korfhagen, T. R. et al. Respiratory epithelial cell expression of human transforming growth factor-alpha induces lung fibrosis in transgenic mice. J Clin Invest 93, 1691-9 (1994). (Pubitemid 24116410)
39. Hardie, W. D. et al. Conditional expression of transforming growth factor-alpha in adult mouse lung causes pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 286, L741-9 (2004). (Pubitemid 38365059)
40. Madtes, D. K., Elston, A. L., Hackman, R. C., Dunn, A. R. & Clark, J. G. Transforming growth factor-alpha deficiency reduces pulmonary fibrosis in transgenic mice. Am J Respir Cell Mol Biol 20, 924-34 (1999). (Pubitemid 129544270)
41. Le Cras, T. D., Hardie, W. D., Fagan, K., Whitsett, J. A. & Korfhagen, T. R. Disrupted pulmonary vascular development and pulmonary hypertension in transgenic mice overexpressing transforming growth factor-alpha. Am J Physiol Lung Cell Mol Physiol 285, L1046-54 (2003). (Pubitemid 37310094)
42. Li, L., Li, W. F., Cai, L., Yuan, W. F. & Huang, W. J. Gefitinib inhibits alphasmooth muscle actin expression in mice with bleomycin-induced lung fibrosis. Nan Fang Yi Ke Da Xue Xue Bao 30, 2675-8 (2010).
43. Wang, P. et al. Gefitinib attenuates murine pulmonary fibrosis induced by bleomycin. Chin Med J (Engl) 123, 2259-64 (2010).
44. Hardie, W. D. et al. EGF receptor tyrosine kinase inhibitors diminish transforming growth factor-alpha-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 294, L1217-25 (2008).
45. Miyake, K. et al. Epidermal growth factor receptor-tyrosine kinase inhibitor (gefitinib) augments pneumonitis, but attenuates lung fibrosis in response to radiation injury in rats. J Med Invest 59, 174-85 (2012).
46. Namba, T., Tanaka, K., Hoshino, T., Azuma, A. & Mizushima, T. Suppression of expression of heat shock protein 70 by gefitinib and its contribution to pulmonary fibrosis. PLoS One 6, e27296 (2011).
47. Suzuki, H., Aoshiba, K., Yokohori, N. & Nagai, A. Epidermal growth factor receptor tyrosine kinase inhibition augments a murine model of pulmonary fibrosis. Cancer Res 63, 5054-9 (2003). (Pubitemid 37025129)
48. Rudin, C. M. et al. Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol 26, 1119-27 (2008).
49. Shahbazi, M. et al. Association between functional polymorphism in EGF gene and malignant melanoma. Lancet 359, 397-401 (2002). (Pubitemid 34158948)
50. Li, T. F., Ren, K. W. & Liu, P. F. Meta-analysis of epidermal growth factor polymorphisms and cancer risk: involving 9,779 cases and 15,932 controls. DNA Cell Biol 31, 568-74 (2012).